A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PBSC / peripheral blood stem cell

[Related PubMed/MEDLINE]
Total Number of Papers: 1347
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PBSC  (>> Co-occurring Abbreviation)
Long Form:   peripheral blood stem cell
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A new protocol for improving efficiency of autologous peripheral blood stem cell collection in patients with high white blood cell counts. CE, MNC, STP, WBC
2020 Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening. FISH, G-CSF, NGS
2020 Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. DFS, GRFS, PTCy
2020 Allogeneic Peripheral Blood Stem Cell Transplant: Correlation of Donor Factors with Yield, Engraftment, Chimerism, and Outcome: Retrospective Review of a Single Institute During a 3-Year Period. CD, GVHD, MUD
2020 Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. AML, ATG, BM, cGVHD, CI, GRFS, GRSF, GVHD, HLA, HR
2020 Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ASCT, ATG, GVHD
2020 Assessment of haematopoietic progenitor cell counting with the Sysmex XN-1000 to guide timing of apheresis of peripheral blood stem cells. MM, PB
2020 Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). aAA, AIC, AIHA, AIN, ATG, BM, EBMT, ITP, RIC
2020 Comparison of spectra optia and amicus cell separators for autologous peripheral blood stem cell collection. cMNC, PLT
10  2020 CTLA4Ig Limits Both Incidence and Severity of Early Cytokine Release Syndrome following Haploidentical Peripheral Blood Stem Cell Transplantation. CRS, PTCy
11  2020 Cytokine release syndrome after allogeneic stem cell transplantation with post-transplant cyclophosphamide. CRS, GVHD, haplo-HSCT, PTCy, TNC
12  2020 Effect of high nucleated cell concentration on product viability and hematopoietic recovery in autologous transplantation. ANC, DMSO, NC
13  2020 Effect of Stem Cell Source and Dose on Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Idiopathic Aplastic Anemia: Data from the Korean Aplastic Anemia Trials. AA, ADs, allo-HSCT, BM, GVHD, OS
14  2020 Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. ASCT, GDP, R/R
15  2020 Evaluation of the Sysmex XN automated hematopoietic progenitor cell enumeration for timing of peripheral blood stem cell harvest. HPC
16  2020 Health-related quality of life in peripheral blood stem cell donors and bone marrow donors: a prospective study in Japan. AEs, BM, HRQoL, OR
17  2020 High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide. BM, PTCy
18  2020 High-dose post-transplant cyclophosphamide impairs gammadelta T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. EBV, haplo-HCT, IR, PTCy
19  2020 How old is too old? In vivo engraftment of human peripheral blood stem cells cryopreserved for up to 18 years - implications for clinical transplantation and stability programs. NSG
20  2020 Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. GVHD, haplo-SCT, RIC
21  2020 Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution. ASCT, BW, G-CSF, HD, MM
22  2020 Lower platelet count with increased density of platelet antigens in granulocyte colony-stimulating factor mobilized peripheral blood stem cell donors. FSC, G-CSF
23  2020 Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children. BM, HSCT, MMRD, PIDs, SCID
24  2020 Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. ALL, allo-HSCT, BM, CC, FTBI, FU, LFS, MAC, MRD, NRM, OS, RI, UD
25  2020 Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors. CMV, G-CSF
26  2020 Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant. HDC
27  2020 Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. AML, CR, HDAC, NILG, OS, RFS
28  2020 Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. ATG, GVHD, HHSCT, PTCy
29  2020 Presence of promyelocytes in peripheral blood as a novel predictor of the optimal timing for single-step peripheral blood stem cell collection. ---
30  2020 Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. BM, CRS, haplo-SCT, NRM, OS, PTCy
31  2020 Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. G-CSF
32  2020 Sporting participation following the operative management of chondral defects of the knee at mid-term follow up: a systematic review and meta-analysis. ACI, MACI, OAT, PRISMA, PRP
33  2020 Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma. ABSCT, HD-CHT, MM
34  2020 Successful prevention of severe allergic transfusion reactions with omalizumab. ATRs
35  2020 Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. ATG, CI, CR, DFS, GVHD, haplo-SCT, NRM, OS, PTCy, R/R, RIC, TBF, TEC
36  2020 Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. BMI, G-CSF
37  2020 [Efficacy of photocatalytic air purifiers in reducing dimethyl sulfide malodor following cryopreserved peripheral blood stem cell infusion]. DMS, DMSO
38  2019 Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. HCT, HCT-CI, NRM
39  2019 Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products. ABSCT
40  2019 Comparison of the methods evaluating post thawing viability of peripheral blood stem cell graft. AO/EB, EO, TP
41  2019 Comparison of three mobilization protocols for peripheral blood stem cell apheresis with Spectra Optia continuous mononuclear cell protocol in healthy dogs. CMNC, G-CSF
42  2019 Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. CMV, GVHD, HCT, UCB
43  2019 Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. FFP, HSCTs, PRCA
44  2019 Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study. BV, BW
45  2019 Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. EFS, GVHD, kg-bw, MUD, TCD, TRM
46  2019 Flow cytometric enumeration of CD34+ hematopoietic stem cells: A comparison between single- versus dual-platform methodology using the International Society of Hematotherapy and Graft Engineering protocol. HSC
47  2019 Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. GVHD, HSCT, NRM, URD
48  2019 Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation. allo-HCT, BM, UCB
49  2019 Immunomagnetic selective donor-derived CD4+CCR7+ T cell depletion procedure for peripheral blood stem cells graft. CCR7, GVHD
50  2019 Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years. ---
51  2019 Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. LEN
52  2019 Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. aGVHD, cGVHD, DFS, GVHD, MSD, MUD, NRM, OS
53  2019 Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor. JAK2, PV
54  2019 Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma ASCT, CR, EFS, HL, NHL, OS, PR
55  2019 Molecular characterization of novel Adeno-associated virus variants infecting human tissues. AAV
56  2019 Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant. FIL, HDC, PEG
57  2019 Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation. BM, cGVHD, HSCT
58  2019 Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. BM, Haplo-SCT, PTCy
59  2019 Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. GRFS, GVHD, HSCT, MTX-CsA, PTCy
60  2019 Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. ASCT, MM, RD-plerixafor
61  2019 Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. CMV, DRI, GVHD, HCT, RIC, URD
62  2019 Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. BM, HRQoL, ORs
63  2019 Safety of Pediatric Peripheral Blood Stem Cell Harvest in Daycare Setting: An Institutional Experience. LMA
64  2019 Solving the calcium gluconate shortage in real-time: Mistakes made and lessons learned. ---
65  2019 Successful engraftment after infusion of multiple low doses of CD34+ cells from a poorly matched sibling donor in a patient with severe aplastic anemia. ---
66  2019 The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. BM, HCT, TNCs
67  2019 The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease. ATG, GVHD, HSCT, sib, TRM, URD
68  2018 A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience. ---
69  2018 Adult Stem Cells and Medicine. ASC, BM, CAR T cell, HSC, HSCT, MM
70  2018 Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. BM, GVHD, HR, LFS, OS, PTCy
71  2018 CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. BM, CI, HCT, PTCy
72  2018 CD34+ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. GVHD, HSCT, OS, PGF, SCBs
73  2018 Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors. Cobe, GVHD, HSCT, MNC, TRM
74  2018 Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. ASCT, CI, CPCs, ISS, MM, OS, PFS, VGPR
75  2018 Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. ---
76  2018 Expression of adhesion molecules on CD34+ cells from steady-state bone marrow before and after mobilization and their association with the yield of CD34+ cells. CAMs, HPCs
77  2018 GVHD Prevention in 2018: Tried and True or Something New? GVHD
78  2018 Impact of apheresis automation on procedure quality and predictability of CD34+ cell yield. CBC, CE, WBC
79  2018 Impact of plerixafor (mozobil) on hospital efficiency: A single center experience. ASCT, ECP, G-CSF
80  2018 Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. GVHD, PTCy, RIC
81  2018 Long-Term Safety of Short-Term Administration of Filgrastim (rhG-CSF) and Leukophresis Procedure in Healthy Children: Application of Peripheral Blood Stem Cell Collection in Pediatric Donors. HSCs, rhG-CSF
82  2018 Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. G-alone
83  2018 Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result. ---
84  2018 Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis. G-CSF
85  2018 Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. ASCT, MM, PFS
86  2018 Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. GVHD, HSCT, MTX, MTX15, SAA
87  2018 Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. BM, CR, MIBG, NANTRC, NANTRCv1.0, OS, PD, PFS, PR, RECIST, SD
88  2018 R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. ASCT, HDC, MCL, PFS
89  2018 Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. ATG, CIR, CMV, EBV, GVHD, haplo-HSCT, NRM, OS, PTCy, PTLD, RIC
90  2018 Reflections on methodical approaches to hematopoietic stem cell collection in children. BW
91  2018 T Cell-Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation for Treatment of T-Lymphoblastic Lymphoma. CR, GVHD, haplo-HCT, T-LBL
92  2018 UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. CD, G-CSF
93  2018 Unrelated and related donor transplantation for beta-thalassemia major: A single-center experience from India. GVHD, HSCT, MUD, OS, RD, TFS
94  2018 [Efficiency of DA-EPOCH and MA chemotherapy in the mobilization of autologous peripheral blood stem cells in non-Hodgkin's lymphoma]. PLT, RBC
95  2017 Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor Tcells for refractory severe aplastic anaemia. BMT, GVHD, SAA
96  2017 Biologic injections for osteoarthritis and articular cartilage damage: can we modify disease? HA, MACI, MSC, PRP
97  2017 Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. G-CSF, MM
98  2017 Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. ABSCT, CAD, CTC, G-CSF, HDM, LP
99  2017 Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection. ---
100  2017 Donation of peripheral blood stem cells to unrelated strangers: A thematic analysis. BM